DED is one of the most common ocular conditions in the United States and Europe. Inflammation plays a prominent role in the pathogenesis of DED, and the condition may eventually lead to damage to the ocular surface. Patients can present with different signs and symptoms, making diagnosis and disease management highly complex, particularly for patients with moderate to severe DED. Indeed, few therapies are approved specifically for the treatment of DED in the United States or Europe, with a high failure rate in clinical trials. As such, unmet need remains strong in DED, and multiple opportunities exist for novel therapies that offer improvements over existing options.
QUESTIONS ANSWERED
CONTENT HIGHLIGHTS
Geographies: United States, France, Germany, United Kingdom
Primary Research: Survey of 63 U.S. and 31 European ophthalmologists
Key Drugs Covered: Restasis (U.S.), Xiidra (U.S.), Ikervis (Europe), Cequa (U.S.), KPI-121 0.25%, CyclASol, HL036, voclosporin ophthalmic solution
Key Metrics Included:
Target Product Profile (TPP) simulator based on conjoint analysis methodology.
Stated versus derived importance of product attributes on prescribing behavior.
Assessment of current drug performance against treatment drivers and goals.
Physician perceptions of unmet needs in the indication and related indications.
Analysis of remaining drug development opportunities.
PRODUCT DESCRIPTION
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. Two market scenarios are profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.